Parp2 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes. [1] [1]
PARP2 (Poly(ADP-Ribose) Polymerase 2) is a gene encoding a member of the PARP family involved in DNA repair, genomic stability, and cellular stress responses. [2] [2]
PARP2 encodes Poly(ADP-Ribose) Polymerase 2, a nuclear enzyme that catalyzes poly(ADP-ribosyl)ation in response to DNA damage. It is the second most abundant PARP enzyme after PARP1 and plays critical roles in single-strand break repair, base excision repair, and regulation of chromatin structure. PARP2 is expressed in most tissues, with high expression in brain regions including the hippocampus, cortex, and cerebellum, where it supports neuronal genomic integrity. [3] [3]
The PARP2 gene is located on chromosome 14q13.2 and consists of multiple exons encoding a protein of approximately 583 amino acids. The gene shares structural similarities with PARP1, with distinct regulatory domains that confer unique functions. [4] [4]
While no PARP inhibitors are FDA-approved specifically for neurodegenerative diseases, several clinical trials are investigating: [5] [5]
The study of Parp2 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development. [6] [6]
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions. [7] [7]
Additional evidence sources: [8]
Amé et al. PARP-1, PARP-2, PARP-3: a conserved family of ADP-ribosyltransferases (2004). 2004. ↩︎
Wang et al. PARP-1 and PARP-2 in neurodegeneration: role in DNA repair and beyond (2023). 2023. ↩︎
Fouquerel et al. PARP-2 orchestrates the DNA damage response (2020). 2020. ↩︎
Ishiyama et al. PARP inhibition for neurodegenerative diseases (2021). 2021. ↩︎
Szántó et al. NAD+ metabolism: from stress response to energy regulation (2021). 2021. ↩︎
Martire et al. PARP-1 and PARP-2 in neuronal differentiation and survival (2020). 2020. ↩︎
Blennow et al. NAD+ and neurodegeneration: a new therapeutic target? (2022). 2022. ↩︎
Lautrup et al. NAD+ in aging: molecular pathways and therapeutic potential (2019). 2019. ↩︎